{"id":482855,"date":"2021-04-27T16:34:54","date_gmt":"2021-04-27T20:34:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/"},"modified":"2021-04-27T16:34:54","modified_gmt":"2021-04-27T20:34:54","slug":"freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/","title":{"rendered":"Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">LONDON, April  27, 2021  (GLOBE NEWSWIRE) &#8212; Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the \u201cCompany\u201d or \u201cFreeline\u201d), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will give six poster presentations at the American Society of Gene and Cell Therapy Annual Meeting 2021, taking place May 11 \u2013 14.<\/p>\n<p>\u201cWe are excited to be presenting six posters at the upcoming ASGCT conference, which together highlight the scientific foundation that underlies our gene therapy programs and broader platform technology,\u201d said Theresa Heggie, CEO of Freeline. \u201cThese posters are reflective of steady progress at Freeline, which we expect will include three gene therapies in the clinic by year end.\u201d\u00a0\u00a0<\/p>\n<p>\n        <strong>Poster Presentation Details<\/strong>\n      <\/p>\n<p>\n        <em>#329:<\/em>\u00a0<strong><em>FLT201, a Novel Investigational AAV-Mediated Gene Therapy Candidate for Gaucher Disease Type 1<\/em><\/strong>\u00a0<br \/>Presenter:\u00a0 Romuald\u00a0Corbau, PhD, Chief Scientific Officer<\/p>\n<p>\n        <em>#509:<\/em>\u00a0<strong><em>GLA Uptake and Metabolic Cross Correction in Fabry Disease Relevant Cell Lines: A Rationale for Liver-Directed AAV Gene Therapy<\/em><\/strong>\u00a0<br \/>Presenter:\u00a0Jey Jeyakumar, PhD, Scientific Director\u00a0<\/p>\n<p>\n        <em>#821:<\/em>\u00a0<strong>Development of a 96-Well Plate-Based High-Throughput System for\u00a0rAAV\u00a0Manufacturing Platform Optimization and Candidate Selection<\/strong>\u00a0<br \/>Presenter: Bettina\u00a0Prieler, PhD Student Technology Development\u00a0<\/p>\n<p>\n        <em>#843:<\/em>\u00a0<strong><em>Development and Scale Up of a Suspension Cell-Based AAV Manufacturing Process<\/em><\/strong>\u00a0<br \/>Presenter:\u00a0Ahmed Youssef, Team Leader USP Development\u00a0<\/p>\n<p>\n        <em>#878:\u00a0<\/em><br \/>\n        <strong><br \/>\n          <em>Defining a Reliable Quantification Assay Strategy for Adeno-Associated Virus (AAV)-Based Gene Therapies<\/em><br \/>\n        <\/strong>\u00a0<br \/>Presenter:\u00a0Felicia\u00a0Thoennissen, PhD, Scientist Analytical Development\u00a0<\/p>\n<p>\n        <em>#894:<\/em>\u00a0<strong><em>Development of an Assay to Measure Transduction Efficiency of Adeno-Associated Virus (AAV)-Based Gene Therapies<\/em><\/strong>\u00a0<br \/>Presenter:\u00a0Anita Heinlein, Scientist Analytical Development\u00a0<\/p>\n<p>Abstracts will be available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BxWeRsj2NrGBA98-02MPZQsFDdy9pav-g7IxQEkHZtvb2Isl53xunqu_9-t_s03672L7I0VK1c14ErxqAHEgvTxwZmVzQdU_w5jlAMsD_N0=\" rel=\"nofollow noopener\" target=\"_blank\">ASGCT website<\/a> starting today.<\/p>\n<p>\n        <strong>About Freeline Therapeutics<\/strong>\n      <\/p>\n<p>Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (\u201cAAV\u201d) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient\u2019s bloodstream. The Company\u2019s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains statements that constitute \u201cforward looking statements\u201d as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company\u2019s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the Company\u2019s research, pipeline and clinical trial plans. In some cases, you can identify such forward-looking statements by terminology such as \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cseek,\u201d \u201cproject\u201d or \u201cexpect,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould\u201d or \u201cshould,\u201d the negative of these terms or similar expressions. Forward looking statements are based on management\u2019s current beliefs and assumptions and on information currently available to the Company, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks and uncertainties, including the Company\u2019s recurring losses from operations; the development of the Company\u2019s product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical studies or trials and related preparatory work and regulatory review; the Company\u2019s ability to design and implement successful clinical trials for its product candidates; the potential for a pandemic, epidemic or outbreak of infectious diseases in the US, UK or EU, including the COVID-19 pandemic, to disrupt the Company\u2019s clinical trial pipeline; the Company\u2019s failure to demonstrate the safety and efficacy of its product candidates; the fact that results obtained in earlier stage clinical testing may not be indicative of results in future clinical trials; the Company\u2019s ability to enroll patients in clinical trials for its product candidates; the possibility that one or more of the Company\u2019s product candidates may cause serious adverse, undesirable or unacceptable side effects or have other properties that could delay or prevent their regulatory approval or limit their commercial potential; the Company\u2019s ability to obtain and maintain regulatory approval of its product candidates; the Company\u2019s limited manufacturing experience which could result in delays in the development, regulatory approval or commercialization of its product candidates; and the Company\u2019s ability to identify or discover additional product candidates, or failure to capitalize on programs or product candidates. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company\u2019s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference the Company\u2019s reports and documents filed with the U.S. Securities and Exchange Commission. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.<\/p>\n<p>\n        <strong>Contact <\/strong>\n      <\/p>\n<p>David S. Arrington<br \/>Vice President Investor Relations &amp; Corporate Communications<br \/>Freeline Therapeutics<br \/>david.arrington@freeline.life<br \/>+1 (646) 668 6947<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDc4NyM0MTQxMzE4IzIyMDAzNjk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/5ba9155e-6286-4944-828f-9640e26ff30f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON, April 27, 2021 (GLOBE NEWSWIRE) &#8212; Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the \u201cCompany\u201d or \u201cFreeline\u201d), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will give six poster presentations at the American Society of Gene and Cell Therapy Annual Meeting 2021, taking place May 11 \u2013 14. \u201cWe are excited to be presenting six posters at the upcoming ASGCT conference, which together highlight the scientific foundation that underlies our gene therapy programs and broader platform technology,\u201d said Theresa Heggie, CEO of Freeline. \u201cThese posters are reflective of steady progress at Freeline, which we expect will include three gene therapies in the clinic by year end.\u201d\u00a0\u00a0 Poster &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-482855","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON, April 27, 2021 (GLOBE NEWSWIRE) &#8212; Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the \u201cCompany\u201d or \u201cFreeline\u201d), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will give six poster presentations at the American Society of Gene and Cell Therapy Annual Meeting 2021, taking place May 11 \u2013 14. \u201cWe are excited to be presenting six posters at the upcoming ASGCT conference, which together highlight the scientific foundation that underlies our gene therapy programs and broader platform technology,\u201d said Theresa Heggie, CEO of Freeline. \u201cThese posters are reflective of steady progress at Freeline, which we expect will include three gene therapies in the clinic by year end.\u201d\u00a0\u00a0 Poster &hellip; Continue reading &quot;Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-27T20:34:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDc4NyM0MTQxMzE4IzIyMDAzNjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021\",\"datePublished\":\"2021-04-27T20:34:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/\"},\"wordCount\":923,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDc4NyM0MTQxMzE4IzIyMDAzNjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/\",\"name\":\"Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDc4NyM0MTQxMzE4IzIyMDAzNjk=\",\"datePublished\":\"2021-04-27T20:34:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDc4NyM0MTQxMzE4IzIyMDAzNjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDc4NyM0MTQxMzE4IzIyMDAzNjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/","og_locale":"en_US","og_type":"article","og_title":"Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021 - Market Newsdesk","og_description":"LONDON, April 27, 2021 (GLOBE NEWSWIRE) &#8212; Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the \u201cCompany\u201d or \u201cFreeline\u201d), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will give six poster presentations at the American Society of Gene and Cell Therapy Annual Meeting 2021, taking place May 11 \u2013 14. \u201cWe are excited to be presenting six posters at the upcoming ASGCT conference, which together highlight the scientific foundation that underlies our gene therapy programs and broader platform technology,\u201d said Theresa Heggie, CEO of Freeline. \u201cThese posters are reflective of steady progress at Freeline, which we expect will include three gene therapies in the clinic by year end.\u201d\u00a0\u00a0 Poster &hellip; Continue reading \"Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-27T20:34:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDc4NyM0MTQxMzE4IzIyMDAzNjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021","datePublished":"2021-04-27T20:34:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/"},"wordCount":923,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDc4NyM0MTQxMzE4IzIyMDAzNjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/","name":"Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDc4NyM0MTQxMzE4IzIyMDAzNjk=","datePublished":"2021-04-27T20:34:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDc4NyM0MTQxMzE4IzIyMDAzNjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDc4NyM0MTQxMzE4IzIyMDAzNjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=482855"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482855\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=482855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=482855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=482855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}